Y. Mori, Toshie Mori, K. Adachi, S. Abe, Y. Oshima, A. Takeuchi, Makoto Ito
{"title":"Volumetric-modulated arc stereotactic radiotherapy for intramedullary cervical spinal cord metastases: Report of two cases","authors":"Y. Mori, Toshie Mori, K. Adachi, S. Abe, Y. Oshima, A. Takeuchi, Makoto Ito","doi":"10.18869/ACADPUB.IJRR.18.3.599","DOIUrl":null,"url":null,"abstract":"The treatment results of intensity-modulated stereotactic radiotherapy (IMSRT) by volumetric-modulated arc therapy (VMAT) for intramedullary cervical spinal cord metastases (IMCSCM) in two cases were presented. Case 1: A 76year-old woman showed left-sided motor weakness and left arm pain and dysesthesia due to IMCSCM at C [cervical] 6-7 (located a little to the left laterally) with multiple small brain metastases from thyroid carcinoma. Multiple brain metastases were successfully treated by stereotactic radiosurgery (SRS). In addition, IMCSCM was treated by IM-SRT. Case 2: A 48year-old man presented with asymptomatic IMCSCM at C2 (located a little to the right laterally) after conventional whole brain radiotherapy (WBRT) and multiple sessions of SRS/SRT for multiple brain metastases from lung adenocarcinoma. IMCSCM was treated by IM-SRT. In both cases 39 Gy in 13 fractions (without PTV [planning target volume] margin, D95%=95% dose) was delivered to the IMCSCM (0.3 ml and 0.5 ml in volume respectively) by coplanar 2-full circular arc VMAT. The maximum dose to the tumor was 46.3 Gy in case 1 and 47.1 Gy in case 2. IMCSCM in both cases shrank markedly without adverse effects during the follow-up period of 32 months and 8 months respectively. The symptoms of the extremities in case 1 were subsided completely until the patient’s death at 34 months after SRT from lung metastasis. In case 1 IMCSCM had been thought to be a relatively radioresistant thyroid carcinoma metastasis. In case 2 IMCSCM was near the field of the prior WBRT. However, both tumors were successfully treated without adverse effects by VMAT IM-SRT.","PeriodicalId":14498,"journal":{"name":"Iranian Journal of Radiation Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Radiation Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18869/ACADPUB.IJRR.18.3.599","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0
Abstract
The treatment results of intensity-modulated stereotactic radiotherapy (IMSRT) by volumetric-modulated arc therapy (VMAT) for intramedullary cervical spinal cord metastases (IMCSCM) in two cases were presented. Case 1: A 76year-old woman showed left-sided motor weakness and left arm pain and dysesthesia due to IMCSCM at C [cervical] 6-7 (located a little to the left laterally) with multiple small brain metastases from thyroid carcinoma. Multiple brain metastases were successfully treated by stereotactic radiosurgery (SRS). In addition, IMCSCM was treated by IM-SRT. Case 2: A 48year-old man presented with asymptomatic IMCSCM at C2 (located a little to the right laterally) after conventional whole brain radiotherapy (WBRT) and multiple sessions of SRS/SRT for multiple brain metastases from lung adenocarcinoma. IMCSCM was treated by IM-SRT. In both cases 39 Gy in 13 fractions (without PTV [planning target volume] margin, D95%=95% dose) was delivered to the IMCSCM (0.3 ml and 0.5 ml in volume respectively) by coplanar 2-full circular arc VMAT. The maximum dose to the tumor was 46.3 Gy in case 1 and 47.1 Gy in case 2. IMCSCM in both cases shrank markedly without adverse effects during the follow-up period of 32 months and 8 months respectively. The symptoms of the extremities in case 1 were subsided completely until the patient’s death at 34 months after SRT from lung metastasis. In case 1 IMCSCM had been thought to be a relatively radioresistant thyroid carcinoma metastasis. In case 2 IMCSCM was near the field of the prior WBRT. However, both tumors were successfully treated without adverse effects by VMAT IM-SRT.
期刊介绍:
Iranian Journal of Radiation Research (IJRR) publishes original scientific research and clinical investigations related to radiation oncology, radiation biology, and Medical and health physics. The clinical studies submitted for publication include experimental studies of combined modality treatment, especially chemoradiotherapy approaches, and relevant innovations in hyperthermia, brachytherapy, high LET irradiation, nuclear medicine, dosimetry, tumor imaging, radiation treatment planning, radiosensitizers, and radioprotectors. All manuscripts must pass stringent peer-review and only papers that are rated of high scientific quality are accepted.